Company Filing History:
1 out of 31 
1 out of 336 
Years Active: 2020
Title: The Innovative Contributions of Yaara Ofir-Rosenfeld
Introduction
Yaara Ofir-Rosenfeld is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of cancer treatment through his innovative research and development of therapeutic methods. His work focuses on exploiting synthetic lethality and enhancing the effectiveness of chemotherapy.
Latest Patents
Yaara Ofir-Rosenfeld holds a patent titled "Methods of screening and treatment with USP4 inhibitors." This patent relates to materials and methods for exploiting synthetic lethality and/or chemo-sensitisation in DNA damage response (DDR) pathways. Specifically, it addresses the ubiquitin hydrolase protein Ubiquitin Specific Protease 4 (USP4) and its association with DDR pathways. The patent describes the use of USP4 inhibitors in cancer treatment, particularly for tumours that are defective in double-strand break repair (DSBR) or resistant to platinum-based chemotherapy. It also discusses methods to sensitise tumours to other therapeutic agents.
Career Highlights
Throughout his career, Yaara Ofir-Rosenfeld has worked with various companies, including Mission Therapeutics Limited and Cambridge Enterprise Limited. His experience in these organizations has contributed to his expertise in the field of cancer research and treatment.
Collaborations
Yaara has collaborated with notable individuals in his field, including Xavier Jacq and Helen Robinson. These collaborations have further enhanced his research and development efforts.
Conclusion
Yaara Ofir-Rosenfeld's innovative work in cancer treatment through the development of USP4 inhibitors showcases his commitment to advancing medical science. His contributions are significant in the ongoing fight against cancer, and his patent reflects the potential for improved therapeutic strategies.